Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gufic Biosciences's Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1,173 Mil. Therefore, Gufic Biosciences's EV-to-EBIT ratio for today is 32.74.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Gufic Biosciences's Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1,383 Mil. Therefore, Gufic Biosciences's EV-to-EBITDA ratio for today is 27.76.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Gufic Biosciences's Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₹8,198 Mil. Therefore, Gufic Biosciences's EV-to-Revenue ratio for today is 4.68.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Gufic Biosciences Enterprise Value Historical Data
The historical data trend for Gufic Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gufic Biosciences's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Gufic Biosciences's Enterprise Value for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Gufic Biosciences's current Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,173 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Gufic Biosciences's current Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,383 Mil.
Gufic Biosciences's current Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,198 Mil.
Gufic Biosciences's current Enterprise Value is ₹38,394 Mil.
Gufic Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Gufic Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:509079 has been successfully added to your 